Skip to Main Content

Paper Details

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Invest New Drugs
13
2022

Datasets

Release 1.2